An analysis of the 2015 SPRINT trial has found that, if participants continued taking their antihypertensive medications for the remainder of their lives, intensive blood pressure control could add between six months and three years to their lifespan.

The diabetes drug dulaglutide—sold commercially as Trulicity—has received an expanded indication for the reduction of major adverse cardiovascular events in adults with type 2 diabetes and established CVD or CV risk factors.

The FDA has approved bempedoic acid as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia.

Six barbershops in the Toledo, Ohio, area have implemented CV awareness programs that specifically target black men, CBS affiliate WTOL reported Feb. 14.

An analysis of major cardiology journals in both the U.S. and Europe underlines the stark sex gap in cardiology, revealing that, between 1998 and 2018, there were no women editors-in-chief for U.S. general cardiology journals and only one woman editor-in-chief for a European journal.

A study published in the European Heart Journal on Feb. 18 suggests healthcare expenditures in Europe would skyrocket if local systems adopted experts’ latest guidelines for cholesterol-lowering treatment.

Many Americans who can’t afford prescription insulin for their diabetes are turning to unregulated, illegal markets for discounted products, researchers reported in JAMA Internal Medicine this month.

Some 20% of children have high blood pressure, WBAL-TV reported Feb. 17.